Clinical Trials Browser

Recruiting × trastuzumab deruxtecan × Clear all

NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2 Recruiting

Neoplasm Metastasis

NCT07137416 2026-05-27

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT06819007 2026-05-26

DO-01

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06551220 2026-05-22

HEROIC

Breast Neoplasms

NCT07060807 2026-05-22

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT04585958 2026-05-20

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

Neoplasm Metastasis

NCT07069712 2026-05-18

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06467357 2026-05-14

DESTINY-BTC01

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT04379596 2026-05-13

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06364410 2026-05-13

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT07012031 2026-05-13

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT06764875 2026-05-12

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Phase 2 Recruiting

Unresectable Locally Recurrent Breast Cancer

NCT05993234 2026-05-08

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Gastrointestinal

HER2-positive Advanced Gastric Cancer

NCT06750484 2026-05-06

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Phase 2 Recruiting

Breast Cancer Metastatic

NCT06989112 2026-05-06

DE-01

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05417594 2026-05-05

CERTIS1

Phase 1/2 Recruiting

BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05408845 2026-05-04

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT07124000 2026-05-01

DP-04

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT07340164 2026-04-20

TROY

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

NCT04686305 2026-04-13

DL03

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07198724 2026-04-09

ERADICATE

Phase 1/2 Recruiting

Breast Neoplasms

NCT05950945 2026-04-08

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06486883 2026-04-02

PONTIAC

Phase 2 Recruiting

Advanced Breast Cancer

NCT07371585 2026-03-27

TOP-REAL

Phase 2 Recruiting

Breast Neoplasms

NCT07015697 2026-03-20

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Phase 1 Recruiting

Recurrence

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05376878 2026-02-23

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Phase 4 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT06058988 2026-02-23

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Phase 2 Recruiting

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT07428044 2026-02-23

HERCULES

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07407465 2026-02-17

CHIMERA

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT05945732 2026-02-12

DESTINY Breast Respond HER2-low Europe

Breast Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06244485 2026-02-04

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07022483 2026-02-04

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms

NCT06210776 2026-01-12

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast Neoplasms

NCT06899126 2026-01-08

DESTINY-Lung06

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06085755 2025-12-15

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Phase 1/2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06630130 2025-12-15

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05982678 2025-11-26

ANISE

Phase 2 Recruiting

HER2-positive Breast Cancer

NCT06429761 2025-11-24

STRIDE

Phase 4 Recruiting

Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

Phase 2 Recruiting

Breast Neoplasms

NCT07180264 2025-11-18

Trastuzumab Deruxtecan in Advanced Breast Cancer

Advanced Breast Cancer

NCT04553770 2025-11-10

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06533826 2025-10-24

TRADE DXd

Phase 2 Recruiting

Breast Neoplasms